ALX Oncology Doses First Patient in Phase 1 Dose Escalation Trial Evaluating ADC ALX2004 for the Treatment of EGFR-Expressing Solid Tumors
1. ALX2004, a novel ADC for EGFR-expressing tumors, enters Phase 1 trial. 2. Preclinical data shows favorable safety and dose-dependent anti-tumor activity. 3. Initial safety data from the trial expected in the first half of 2026. 4. Unique design aims to overcome toxicity challenges of previous ADCs. 5. ALX2004 marks a significant milestone for ALX Oncology's drug pipeline.